Skip to content

Study · Non-randomized trial · n = 10 · 1994

5 results

The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.

Lee WA, Ennis RD, Longenecker JP, Bengtsson P

Pharmaceutical research1 May 1994Cited by 46 (Europe PMC)

PMID8058647 (opens in a new tab)DOI10.1023/a:1018992716621 (opens in a new tab)PepBankPUB-08058647
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, the nasal calcitonin formulation with 0.5% STDHF had 3.9% bioavailability at 100 IU relative to the intramuscular dose.

    In plain wordsIn healthy volunteers, nasal calcitonin with the enhancer had 3.9% bioavailability at 100 IU relative to intramuscular calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableBioavailability of enhancer formulation at 100 IU
    Study

    n = 10

    Comparator
    100-IU intramuscular formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 IU · intranasalAs given in this study (human).

    Measurements

    Relative bioavailability
    3.9%
    100 IU intranasal sCT with 0.5% STDHF relative to 100 IU intramuscular dose

    Source sentences

    Summary
    Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively.
    1 context sentence
    Summary · context
    Serum levels of radioimmunoactive salmon calcitonin (sCT) were determined in 10 healthy volunteers after intranasal administration (IN) of 100-, 205-, and 450-IU of sCT with 0.5% sodium tauro-24,25-dihydrofusidate (STDHF), a 200-IU commercial IN formulation, and a 100-IU intramuscular (IM) formulation.
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, the nasal calcitonin formulation with 0.5% STDHF had 7.9% bioavailability at 205 IU relative to the intramuscular dose.

    In plain wordsIn healthy volunteers, nasal calcitonin with the enhancer had 7.9% bioavailability at 205 IU relative to intramuscular calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableBioavailability of enhancer formulation at 205 IU
    Study

    n = 10

    Comparator
    100-IU intramuscular formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    205 IU · intranasalAs given in this study (human).

    Measurements

    Relative bioavailability
    7.9%
    205 IU intranasal sCT with 0.5% STDHF relative to 100 IU intramuscular dose

    Source sentences

    Summary
    Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively.
    1 context sentence
    Summary · context
    Serum levels of radioimmunoactive salmon calcitonin (sCT) were determined in 10 healthy volunteers after intranasal administration (IN) of 100-, 205-, and 450-IU of sCT with 0.5% sodium tauro-24,25-dihydrofusidate (STDHF), a 200-IU commercial IN formulation, and a 100-IU intramuscular (IM) formulation.
  3. 03HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, the nasal calcitonin formulation with 0.5% STDHF had 7.4% bioavailability at 450 IU relative to the intramuscular dose.

    In plain wordsIn healthy volunteers, nasal calcitonin with the enhancer had 7.4% bioavailability at 450 IU relative to intramuscular calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableBioavailability of enhancer formulation at 450 IU
    Study

    n = 10

    Comparator
    100-IU intramuscular formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    450 IU · intranasalAs given in this study (human).

    Measurements

    Relative bioavailability
    7.4%
    450 IU intranasal sCT with 0.5% STDHF relative to 100 IU intramuscular dose

    Source sentences

    Summary
    Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively.
    1 context sentence
    Summary · context
    Serum levels of radioimmunoactive salmon calcitonin (sCT) were determined in 10 healthy volunteers after intranasal administration (IN) of 100-, 205-, and 450-IU of sCT with 0.5% sodium tauro-24,25-dihydrofusidate (STDHF), a 200-IU commercial IN formulation, and a 100-IU intramuscular (IM) formulation.
  4. 04HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, commercial nasal calcitonin had average bioavailability of 1.6% relative to the intramuscular dose.

    In plain wordsIn healthy volunteers, commercial nasal calcitonin had 1.6% average bioavailability relative to intramuscular calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableCommercial nasal formulation bioavailability
    Study

    n = 10

    Comparator
    100-IU intramuscular formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    200 IU · intranasalAs given in this study (human).

    Measurements

    Average relative bioavailability
    1.6%
    200 IU commercial intranasal formulation relative to 100 IU intramuscular dose

    Source sentences

    Summary
    The 200-IU commercial formulation resulted in serum levels above the limit of detection in only 5 of 10 patients, with an average bioavailability of 1.6%.
    2 context sentences
    Summary · context
    Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively.
    Summary · context
    Serum levels of radioimmunoactive salmon calcitonin (sCT) were determined in 10 healthy volunteers after intranasal administration (IN) of 100-, 205-, and 450-IU of sCT with 0.5% sodium tauro-24,25-dihydrofusidate (STDHF), a 200-IU commercial IN formulation, and a 100-IU intramuscular (IM) formulation.
  5. 05HumanNon-randomized trialPharmacokinetics

    In healthy volunteers, the commercial nasal calcitonin formulation produced detectable serum levels in only 5 of 10 participants.

    In plain wordsIn healthy volunteers, commercial nasal calcitonin produced detectable blood levels in only 5 of 10 participants.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableDetectable serum calcitonin after commercial nasal formulation
    Study

    n = 10

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    200 IU · intranasalAs given in this study (human).

    Measurements

    Participants with serum levels above detection limit
    5 participants
    200 IU commercial intranasal formulation; 10 participants tested

    Source sentences

    Summary
    The 200-IU commercial formulation resulted in serum levels above the limit of detection in only 5 of 10 patients, with an average bioavailability of 1.6%.
    1 context sentence
    Summary · context
    Serum levels of radioimmunoactive salmon calcitonin (sCT) were determined in 10 healthy volunteers after intranasal administration (IN) of 100-, 205-, and 450-IU of sCT with 0.5% sodium tauro-24,25-dihydrofusidate (STDHF), a 200-IU commercial IN formulation, and a 100-IU intramuscular (IM) formulation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.